Descrizione del progetto
Verso nuovi biofarmaci che intervengono sul sistema nervoso centrale
Milioni di cittadini europei sono affetti da disturbi del sistema nervoso centrale quali la sclerosi multipla, il morbo di Alzheimer e il morbo di Parkinson. Attualmente, i farmaci con biodisponibilità ridotta per il sistema nervoso centrale vengono somministrati direttamente al suo interno tramite iniezioni intratecali, intracerebroventricolari e intraparenchimali, le quali, tuttavia, richiedono un intervento chirurgico. Per affrontare questa limitazione, il progetto Bio2Brain, finanziato dall’UE, formerà alcuni ricercatori all’inizio della carriera per sviluppare tecnologie innovative al fine di somministrare biofarmaci in sicurezza tramite la via nasale. I risultati del progetto affronteranno la disponibilità ridotta dei farmaci che intervengono sul sistema nervoso centrale, tra cui biofarmaci quali gli anticorpi monoclonali, una sfida tuttora importante per il trattamento di tali disturbi.
Obiettivo
Bio2Brain aims to create a trans-European network of industrially oriented specialists fully trained and experienced, a significant driving force in innovating novel technologies to deliver biopharmaceuticals safely and via the nasal route of administration to the central nervous system (CNS). Diseases of the CNS and the spinal cord affect around 165 million Europeans with disorders such as Multiple Sclerosis, Alzheimer’s disease and Parkinson’s disease. CNS disorders are often connected with high morbidity, significant side effects, suffering of the patients and their families, as well as an enormous burden on the welfare systems. Therefore, in terms of social sustainability, Bio2Brain contributes to increased benefit for both, the society as whole and particularly for those individuals at a disadvantage through these disorders. A highly critical challenge of CNS diseases is the low central availability drugs in general and in particular of biopharmaceuticals like monoclonal antibodies (mAbs). Hence, approved medicinal products with a low CNS bioavailability are currently delivered via intrathecal, intracerebroventricular or intraparenchymal injections. In this way, they are delivered directly to the CNS. Unfortunately, such delivery systems are invasive, require a surgery with high risks, have a low patient compliance and are poorly controllable. Therefore, there is a critical need for a more safe and effective new approach, that means a paradigm shift, for drug delivery technologies in the treatment of CNS diseases. The Bio2Brain network will create a research environment for the interdisciplinary and intersectorial training of 13 ESRs supported by 11 academic teams (beneficiaries and partner universities), 6 key industrial stakeholders and an academic non-profit organization. As an important benefit, the close and frequent exposure of the ESRs to the private sector and to key technologies will significantly enhance their employability.
Campo scientifico
Parole chiave
Programma(i)
Argomento(i)
Meccanismo di finanziamento
MSCA-ITN - Marie Skłodowska-Curie Innovative Training Networks (ITN)Coordinatore
80686 Munchen
Germania